Texas Administrative Code
Title 22 - EXAMINING BOARDS
Part 9 - TEXAS MEDICAL BOARD
Chapter 170 - STANDARDS FOR USE OF INVESTIGATIONAL AGENTS
Subchapter B - INVESTIGATIONAL STEM CELL TREATMENTS FOR PATIENTS WITH CERTAIN SEVERE CHRONIC DISEASES OR TERMINAL ILLNESSES
Section 170.5 - General Standards for the Use of Investigational Stem Cell Treatments for Patients with Certain Severe Chronic Diseases or Terminal Illnesses
Current through Reg. 50, No. 13; March 28, 2025
In accordance with Chapter 1003 of the Texas Health and Safety Code, physicians who administer or provide for the use of investigational stem cell treatments must:
(1) comply with all applicable state and federal laws and rules;
(2) be certified to administer stem cell in accordance with § 1003.055 of the Texas Health and Safety Code;
(3) ensure the patient is enrolled in a clinical trial investigating the use of adult stem cells in humans;
(4) maintain adequate medical records including documentation of the patient's qualifying severe chronic disease or terminal illness;
(5) obtain a signed written informed consent including the patient eligibility determination found in §1003.053(2)(a) of the Texas Health and Safety Code; and
(6) provide stem cells in a qualifying facility.